AVDL
Price
$7.75
Change
-$0.25 (-3.12%)
Updated
Jan 17 closing price
Capitalization
1.53B
54 days until earnings call
CYTH
Price
$0.80
Change
+$0.02 (+2.56%)
Updated
Jan 17 closing price
Capitalization
39.05M
58 days until earnings call
Ad is loading...

AVDL vs CYTH

Header iconAVDL vs CYTH Comparison
Open Charts AVDL vs CYTHBanner chart's image
Avadel Pharmaceuticals
Price$7.75
Change-$0.25 (-3.12%)
Volume$1.14M
Capitalization1.53B
Cyclo Therapeutics
Price$0.80
Change+$0.02 (+2.56%)
Volume$16.87K
Capitalization39.05M
AVDL vs CYTH Comparison Chart
Loading...
AVDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVDL vs. CYTH commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVDL is a Hold and CYTH is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (AVDL: $7.75 vs. CYTH: $0.80)
Brand notoriety: AVDL: Notable vs. CYTH: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AVDL: 75% vs. CYTH: 37%
Market capitalization -- AVDL: $1.53B vs. CYTH: $39.05M
AVDL [@Pharmaceuticals: Other] is valued at $1.53B. CYTH’s [@Pharmaceuticals: Other] market capitalization is $39.05M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVDL’s FA Score shows that 0 FA rating(s) are green whileCYTH’s FA Score has 0 green FA rating(s).

  • AVDL’s FA Score: 0 green, 5 red.
  • CYTH’s FA Score: 0 green, 5 red.
According to our system of comparison, both AVDL and CYTH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVDL’s TA Score shows that 4 TA indicator(s) are bullish while CYTH’s TA Score has 4 bullish TA indicator(s).

  • AVDL’s TA Score: 4 bullish, 3 bearish.
  • CYTH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AVDL is a better buy in the short-term than CYTH.

Price Growth

AVDL (@Pharmaceuticals: Other) experienced а -1.90% price change this week, while CYTH (@Pharmaceuticals: Other) price change was +28.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.23%. For the same industry, the average monthly price growth was +2.88%, and the average quarterly price growth was -9.56%.

Reported Earning Dates

AVDL is expected to report earnings on May 07, 2025.

CYTH is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.23% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVDL($1.53B) has a higher market cap than CYTH($39.1M). CYTH YTD gains are higher at: 35.593 vs. AVDL (-26.261). CYTH has higher annual earnings (EBITDA): -20.03M vs. AVDL (-149.12M). AVDL has more cash in the bank: 105M vs. CYTH (9.25M). CYTH has less debt than AVDL: CYTH (1.03M) vs AVDL (2.62M). AVDL has higher revenues than CYTH: AVDL (28M) vs CYTH (1.08M).
AVDLCYTHAVDL / CYTH
Capitalization1.53B39.1M3,913%
EBITDA-149.12M-20.03M744%
Gain YTD-26.26135.593-74%
P/E RatioN/AN/A-
Revenue28M1.08M2,602%
Total Cash105M9.25M1,136%
Total Debt2.62M1.03M254%
FUNDAMENTALS RATINGS
AVDL vs CYTH: Fundamental Ratings
AVDL
CYTH
OUTLOOK RATING
1..100
5527
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
9459
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
509

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVDL's Valuation (85) in the Medical Specialties industry is in the same range as CYTH (94) in the null industry. This means that AVDL’s stock grew similarly to CYTH’s over the last 12 months.

AVDL's Profit vs Risk Rating (79) in the Medical Specialties industry is in the same range as CYTH (100) in the null industry. This means that AVDL’s stock grew similarly to CYTH’s over the last 12 months.

AVDL's SMR Rating (98) in the Medical Specialties industry is in the same range as CYTH (100) in the null industry. This means that AVDL’s stock grew similarly to CYTH’s over the last 12 months.

CYTH's Price Growth Rating (59) in the null industry is somewhat better than the same rating for AVDL (94) in the Medical Specialties industry. This means that CYTH’s stock grew somewhat faster than AVDL’s over the last 12 months.

AVDL's P/E Growth Rating (52) in the Medical Specialties industry is somewhat better than the same rating for CYTH (100) in the null industry. This means that AVDL’s stock grew somewhat faster than CYTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVDLCYTH
RSI
ODDS (%)
Bullish Trend 5 days ago
69%
N/A
Stochastic
ODDS (%)
Bullish Trend 5 days ago
75%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bearish Trend 5 days ago
82%
Bullish Trend 5 days ago
88%
MACD
ODDS (%)
Bearish Trend 5 days ago
82%
Bullish Trend 5 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
82%
Bullish Trend 5 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
84%
Bullish Trend 5 days ago
84%
Advances
ODDS (%)
Bullish Trend 16 days ago
82%
Bullish Trend 5 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
81%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Ad is loading...
AVDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

AVDL and

Correlation & Price change

A.I.dvisor tells us that AVDL and RMTI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVDL and RMTI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVDL
1D Price
Change %
AVDL100%
-3.13%
RMTI - AVDL
29%
Poorly correlated
+0.95%
PROC - AVDL
29%
Poorly correlated
-2.29%
BNXTF - AVDL
22%
Poorly correlated
N/A
ASRT - AVDL
21%
Poorly correlated
+2.83%
ETON - AVDL
21%
Poorly correlated
+0.91%
More

CYTH and

Correlation & Price change

A.I.dvisor tells us that CYTH and EVOK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYTH and EVOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTH
1D Price
Change %
CYTH100%
+2.37%
EVOK - CYTH
22%
Poorly correlated
-1.35%
TEVA - CYTH
21%
Poorly correlated
+1.11%
PAHC - CYTH
20%
Poorly correlated
-0.53%
HYPMY - CYTH
20%
Poorly correlated
-0.49%
AVDL - CYTH
20%
Poorly correlated
-3.13%
More